Steve Profit – General Manager, Novo Nordisk Taiwan
Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to…
Address: 7F-1, No.216, Sec.2, Tun Hua South Road, Taipei 106, Taiwan
,Taiwan
Tel: (02)2377-2566
Web: http://www.novonordisk.com.tw/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk Taiwan received several awards from patients associations, mainly for supporting those organisations’ activities such as diabetes patients’ camps or patients’ clubs via booth or speech programs. Novo Nordisk Taiwan received an award from Taiwan Diabetes Association for special dedication and contribution during World Diabetes Day 2007.
Pharmaceuticals
Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to…
Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan…
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to…
A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not…
Charles Lin discusses the impact of investment in R&D on Lotus’s product line, and how this has shaped the competitive value of the company over the last decade, as well…
In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan…
Dr. Wen, can you please explain the vision behind Mycenax, and the areas in which you are currently focused? Here at Mycenax, our vision is from bench to better life…
Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might…
The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away…
Phytohealth is a trailbalzer in the Taiwanese biotech industry: the first publically-listed biopharma company in the country, and the first company to receive NDA approval for a Botanical New Drug.…
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Mr. Fang-Yue Lin was a Department of Health Minister before becoming Superintendent of TVGH just 7 short months ago. He shares with us his Insight to the reform of the…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
See our Cookie Privacy Policy Here